EMA Safety Review: GLP-1 Drugs and Mental Health

In July 2023, the European Medicines Agency launched a formal safety review of GLP-1 receptor agonists after reports of suicidal ideation and self-harm. In April 2024, they concluded: no causal relationship established. The FDA reached a similar conclusion. Here's the full evidence trail.

The mental health signal emerged from pharmacovigilance databases — spontaneous adverse event reports submitted by patients and clinicians to regulatory authorities. A small number of reports described suicidal thoughts, self-harm, or depression in patients taking liraglutide or semaglutide. The reports were enough to trigger formal reviews by both the EMA and FDA, but the question was whether these events were caused by the drugs or were coincidental in a population with high baseline rates of depression and psychological distress.

What the EMA Reviewed

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) examined spontaneous adverse event reports, clinical trial safety databases, published literature, and epidemiological studies. The review covered semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity), among others.

The committee assessed whether the reported rates of suicidal ideation and self-harm exceeded what would be expected in the general population of patients with obesity and diabetes — conditions that independently carry elevated rates of depression and suicidality. After reviewing all available evidence, PRAC concluded that the data did not support a causal association and that the observed reports were consistent with background rates.

The FDA's Parallel Evaluation

The FDA conducted its own evaluation and reached a similar conclusion. In January 2024, the FDA stated that preliminary evaluation of reports of suicidal thoughts or actions did not show a causal relationship with GLP-1 receptor agonists. The agency noted that it would continue monitoring but did not require labeling changes related to suicidality.

Epidemiological Evidence

A large Icelandic nationwide registry study, along with several other population-level analyses, examined the association between GLP-1 drug use and psychiatric outcomes. These studies generally found no increased risk of suicidal behavior or major depressive episodes in GLP-1 users compared to matched controls. Some analyses actually showed reduced rates of depression-related outcomes in GLP-1 users, possibly mediated by weight loss and improved metabolic health, though this finding requires cautious interpretation.

Clinical trial data from the STEP, SURMOUNT, and SELECT programs also did not show statistically significant increases in suicidal ideation or depression scores in drug-treated patients versus placebo. However, most trials excluded patients with active psychiatric illness, limiting the ability to detect signals in the highest-risk population.

What Clinicians Should Consider

While no causal link has been established, the clinical context matters. Patients with obesity have 2–3 times the baseline prevalence of depression compared to the general population. Rapid body changes, altered eating patterns, and the psychological complexity of weight loss can affect mental health independently of drug pharmacology. Clinicians should monitor mood and psychological well-being as part of comprehensive obesity management, regardless of the specific medication used.